EUCTR2011-001119-30-BE进行中（未招募）不适用
An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma. - 2B3-101-CR-001
to-BBB technologies B.V.0 个研究点目标入组 129 人开始时间: 2011年12月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years.
- •2. Measurable intracranial disease by MRI.
- •3. ECOG Performance Status = 2.
- •4. Estimated life expectancy of at least 8 weeks.
- •5. Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to = grade 2 (as defined by CTCAE version 4.0).
- •6. No evidence of (cortical) cognitive impairment as defined by a Mini-Mental Status Exam (MMSE) score = 25/30.
- •7. Written informed consent according to local guidelines.
- •2B3-101 single agent dose-escalation phase:
- •2B3-101 in combination with trastuzumab dose-escalation phase:
- •Breast cancer brain metastases study- arm of the expansion phase:
- •Patients with pathologically confirmed diagnosis of advanced, recurrent breast cancer with unequivocal evidence of brain metastases that are refractory to standard therapy or for whom no standard therapy exist.
- •Patients with pathologically confirmed diagnosis of advanced breast cancer with newly diagnosed, untreated, brain metastases, which per multi-disciplinary team decision do not require immediate radiotherapy or surgery.
- •Patients with histologically-confirmed HER2-positive adenocarcinoma of the breast with unequivocal evidence of brain metastases that are refractory to standard therapy or for which no standard therapy exist or with unequivocal evidence of newly diagnosed untreated brain metastases, which per the multi-disciplinary team decision do not require immediate radiotherapy or surgery
- •SCLC brain metastases study arm of the expansion phase:
- •Patients with pathologically confirmed diagnosis of advanced, recurrent SCLC with unequivocal evidence of brain metastases that are refractory to standard therapy or for whom no standard therapy exist.
- •Patients with pathologically confirmed diagnosis of advanced SCLC with newly diagnosed, untreated, brain metastases, which per multi-disciplinary team decision do not require immediate radiotherapy or surgery.
- •Melanoma brain metastases study arm of the expansion phase:
- •Patients with pathologically confirmed diagnosis of advanced, recurrent melanoma with unequivocal evidence of brain metastases that are refractory to standard therapy or for whom no standard therapy exist.
- •Patients with pathologically confirmed diagnosis of advanced mel;anoma with newly diagnosed, untreated, brain metastases, which per multi-disciplinary team decision do not require immediate radiotherapy or surgery.
- •Recurrent malignant glioma study- arm of the expansion phase:
- •7 patients with histologically proven glioma grade IV, which is progressive following first line treatment with surgery or biopsy followed by fractionated radiotherapy with concurrent temozolomide-containing chemotherapy.
- •7 patients with histologically confirmed recurrent malignant (WHO grade III and IV) glioma or histologically confirmed low-grade (WHO grade II) glioma with radiographic evidence of malignant transformation by MRI, that are refractory to standard therapy, or for whom no standard therapy exists or do not require immediate standard therapy per the multi-disciplinary team decision.
- •Breast cancer brain metastases extension cohort of the expansion phase arm
- •See expansion phase
- •SCLC brain metastases extension cohort of the expansion phase arm
- •See expansion phase
- •Recurrent glioma extension cohort of the expansion phase arm
- •See expansion phase
- •Are the trial subjects under 18? no
- •Number of subjects for t
排除标准
- •Prior Treatment:
- •1. Less than 1 week since the last treatment of lapatinib, dabrafenib, everolimus, capecitabine, anastrazole, letrozole and exemestane, less than 2 weeks since the last treatment of vemurafenib; less than 4 weeks since the last treatment of trametinib, chemotherapy, biological therapy, immunotherapy and systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), less than 6 weeks for nitrosoureas and mitomycin C and less than 8 weeks for cranial radiotherapy. Previous trastuzumab treatment will be allowed to continue without interruption in patients that are included in either the 2B3-101 dose-escalation phase in combination with trastuzumab or in the breast cancer expansion phase once the MTD for the combination has been established.
- •2. Patients that have received a maximum cumulative dose of free (i.e., non-liposomal) or liposomal doxorubicin > 360mg/m2 or free epirubicin > 600mg/m2
- •Current Treatment:
- •3. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study.
- •Hematology, coagulation and biochemistry:
- •4. Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count < 100 x 109/L or hemoglobin < 6 mmol/L.
- •5. Inadequate liver function, defined as:
- •Serum (total) bilirubin > 1.5 x the Upper Limit of Normal (ULN) for the institution if no liver metastases (> 2 x ULN in patients with liver metastases);
- •Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN if no liver metastases (> 4x ULN in patients with liver metastases);
- •Alkaline phosphatase levels > 2.5 x ULN if no liver metastases (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
- •6. Inadequate renal function, defined as:
- •Serum creatinine > 1.5 x ULN.
- •7. Leptomeningeal carcinomatosis as the only site of CNS involvement.
- •8. Pregnancy or lactation. Serum pregnancy test to be performed in female subjects of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) within 7 days prior to study treatment start, or within 14 days followed by a confirmatory urine pregnancy test within 7 days prior to study treatment start.
- •9. For female subjects of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male subjects who are not surgically sterile or with partners of childbearing potential: absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).
- •10. Major surgical procedure (including open biopsy, excluding central line IV and portacath) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- •11. Grade 3 or 4 motor, sensory, or cranial neuropathy symptoms (as defined by CTCAE version 4.0).
- •12. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic >100mm Hg).
- •13. Clinically significant (i.e. active) cardiovascular disease defined as:
- •Stroke within = 6 months prior to day 1;
- •Transient Ischaemic Attack (TIA) within = 6 months prior to day 1;
- •Myocardial infarction within = 6 months prior to day 1;
- •Unstable angina;
- •New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure (CHF);
研究者
相似试验
进行中（未招募）
不适用
An open-label, early stage, dose rising study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastasesMedDRA version: 14.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001119-30-NLto-BBB technologies B.V.82
招募中
不适用
An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.or recurrent malignant gliomasolid neoplasmssolid tumors and brain metastases10006291NL-OMON39207to-BBB technologies B.V.45
进行中（未招募）
不适用
An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung canceron-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months.EUCTR2004-004252-40-BEovartis Pharma Services AG42
已完成
1 期
An open-label, dose escalation, phase I study to evaluate the tolerability, safety and pharmacokinetics of afuresertib monotherapy and in combination with bortezomib and dexamethasone in Japanese relapsed multiple myeloma patients.Multiple MyelomaJPRN-jRCT2080222524ovartis18
进行中（未招募）
1 期
Trial aimed to find the maximum tolerated dose, the recommended dose and the efficacy of E-3810 in patients with advanced solid tumors.Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwiseor B) progressing after SD ? 6 months or PR to prior antiangiogenic treatmentor C) potentially sensitive to antiangiogenic treatment if no antiangiogenic agents available for that specific condition.MedDRA version: 20.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2010-019121-34-ESInstitut de Recherches Internationales Servier130